Post-stroke fatigue manifests as early exhaustion, reduced energy and an aversion to effort during mental or physical tasks that does not reliably improve with rest. The authors reported prevalence estimates ranging from 30% to 70% of stroke survivors, a broad span that appears independent of stroke severity. Observational data linked persistent fatigue with worse functional outcomes. Depression, sleep disturbance and pain were listed by the study team as recurrent risk factors. While fatigue frequently coexists with depression, the clinical picture differs: patients describe overwhelming physical and cognitive tiredness rather than the persistent sadness or anhedonia characteristic of major depressive disorder.
Fatigue typically emerges within two weeks of the index event; many patients improve by three months, although the cohort showed that about 40% of patients may continue to experience fatigue at two years. The Fatigue Severity Scale (FSS) — a 9-item questionnaire — is the most widely used screening instrument cited. Investigators reported that an FSS score of 4 or higher (on a 7-point scale) indicates clinically important fatigue. The authors recommended incorporating routine screening into primary care and outpatient follow-up visits after stroke to detect persistent or disabling fatigue early in recovery.
Clinicians should actively investigate potentially reversible or treatable causes during recovery. The list of contributors in the report included mood disorders (notably depression), sleep disorders such as obstructive sleep apnea, pain syndromes, ongoing infection, dehydration, hypothyroidism, anemia, nutritional deficiencies and the use of sedating medications. The authors advised that identifying and managing these factors is a first-line clinical task because addressing them may reduce the burden of fatigue and improve rehabilitation participation.
The article emphasized nonpharmacological, team-based management as the mainstay. Patients and caregivers should receive counselling on the nature of post-stroke fatigue and practical strategies: sleep hygiene measures, energy-conservation techniques, planning activities around expected energy demands, prioritizing tasks, sitting to perform chores and delegating low-priority activities. Progressive exercise and graded activity programs were recommended to support physical recovery and facilitate a gradual return to work. The study team observed that targeted rehabilitation and staged activity pacing can improve tolerance for daily tasks. Cognitive behavioural therapy and mindfulness-based stress reduction were noted as potential adjunctive options for some patients. The authors also advised clinicians to encourage explicit communication about rest needs with family members, caregivers, health professionals and employers to align expectations and support recovery.
The authors stated that pharmacologic treatments for post-stroke fatigue are currently limited. Antidepressants were not recommended solely to treat fatigue unless the patient had comorbid depression or anxiety that required pharmacotherapy. The stimulant-like agent modafinil has demonstrated benefit in small trials, but investigators reported that the evidence remains insufficient to support routine use; further, larger studies are needed before recommending modafinil widely. The article did not provide specific dosing regimens or detailed trial data for modafinil; those methodological details were not reported in this Practice summary.
The Practice piece functions as a synthesis of guideline recommendations and systematic-review findings rather than an original trial report; as such, the authors drew attention to remaining evidence gaps, notably the lack of robust pharmacological data. The article included a footnote disclosing competing interests for one author, who reported diverse research funding, consulting fees and other relationships unrelated to the submitted work. No other competing interests were declared. The text was peer reviewed and distributed under an Open Access licence. Specific unanswered clinical questions left open by the summary include the optimal pharmacologic strategy for persistent post-stroke fatigue and the size and design of trials needed to establish efficacy and safety for agents such as modafinil. These questions were noted implicitly through statements calling for additional evidence rather than through explicit trial plans.